Ropivacaine Kabi

Leaflet attached to the packaging: information for the user

Ropivacaine Kabi, 2 mg/ml, solution for injection
Ropivacaine Kabi, 7.5 mg/ml, solution for injection
Ropivacaine Kabi, 10 mg/ml, solution for injection
Ropivacaine hydrochloride

Read the leaflet carefully before using the medicine, as it contains important information for the patient.

­
Keep this leaflet, so you can read it again if you need to.
­
If you have any doubts, consult a doctor, nurse or other healthcare professional.
­
If the patient experiences any side effects, including any not listed in this leaflet, they should tell their doctor, pharmacist
or other healthcare professional. See section 4.
The names of the medicines covered by this leaflet are:
Ropivacaine Kabi, 2 mg/ml, solution for injection
Ropivacaine Kabi, 7.5 mg/ml, solution for injection
Ropivacaine Kabi, 10 mg/ml, solution for injection
In this leaflet, they are referred to collectively as Ropivacaine Kabi.

Table of contents of the leaflet

• 1. What is Ropivacaine Kabi and what is it used for
• 2. Important information before using Ropivacaine Kabi
• 3. How to use Ropivacaine Kabi
• 4. Possible side effects
• 5. How to store Ropivacaine Kabi
• 6. Contents of the packaging and other information

1. What is Ropivacaine Kabi and what is it used for

• Ropivacaine Kabi contains the active substance ropivacaine hydrochloride.
• It belongs to a group of medicines called local anesthetics.

Ropivacaine Kabi, 2 mg/ml, solution for injection is used in adults and children of all ages to treat acute pain. It numbs parts of the body, e.g. after surgical procedures.
Ropivacaine Kabi, 7.5 mg/ml, solution for injection is used in adults and adolescents over 12 years of age to numb parts of the body, to prevent or relieve pain.
It can be used for:

• Numbing parts of the body during surgery, including during cesarean section.
• Relieving pain during childbirth, after surgery or after an accident. Ropivacaine Kabi, 10 mg/ml, solution for injection is used in adults and adolescents over 12 years of age to numb parts of the body during surgical procedures.

2. Important information before using Ropivacaine Kabi

When not to use Ropivacaine Kabi:

allergic(hypersensitive) to ropivacaine hydrochlorideor any of the other ingredients of this medicine (listed in section 6);decreased blood volume(hypovolemia);
• by intravascular administrationfor numbing a specific part of the body;
• or by paracervical administrationfor pain relief during childbirth. If the patient is unsure whether any of the above points apply to them, they should consult a doctor before using Ropivacaine Kabi.

Warnings and precautions

Particular caution should be exercised not to injectRopivacaine Kabi directly
into a blood vesseland not to cause immediate toxic effects.
Injections should not be performed in areas with inflammation.
Before starting treatment with Ropivacaine Kabi, the patient should discuss it with their doctor, nurse
or other healthcare professional:

general weaknessdue to age or other factors,heart disease(partial or complete conduction block),liver disease,kidney problems. The doctor should be informed if the patient has any of the above conditions, as it may be necessary to adjust the dose of Ropivacaine Kabi. Before starting treatment with Ropivacaine Kabi, the patient should discuss it with their doctor, nurse or other healthcare professional:acute porphyria(disorders of red blood cell pigment production, sometimes leading to neurological symptoms). The doctor should be informed if the patient or a family member suffers from porphyria, as it may be necessary to administer a different anesthetic. Before starting treatment, the patient should inform their doctor about any illnesses and current complaints.

Children

Ropivacaine Kabi, 2 mg/ml, solution for injection
Particular caution should be exercised:

• in newborns, as they are more sensitive to Ropivacaine Kabi, 2 mg/ml, solution for injection.
• in children under 12 years of age, as the safety of using Ropivacaine Kabi, 2 mg/ml, solution for injection for numbing certain parts of the body in younger children has not been established. Ropivacaine Kabi 7.5 mg/ml and 10 mg/ml, solution for injection In children under 12 years of age, other concentrations (2 mg/ml and 5 mg/ml) may be more suitable.

Ropivacaine Kabi and other medicines

The patient should tell their doctor or healthcare professional about all medicines
they are currently taking or have recently taken, as well as any medicines they plan to take.
Ropivacaine Kabi may affect the action of some medicines, and certain medicines may also affect
the action of Ropivacaine Kabi.
In particular, the patient should inform their doctor if they are taking any of the following
medicines:

• other local anesthetics,
• strong painkillers, such as morphine or codeine,
• medicines used to treat heart rhythm disorders(arrhythmia), such as lidocaine and mexiletine. The doctor must be informed about the use of these medicines in order to assess the dose of Ropivacaine Kabi that can be administered to the patient. The patient should also inform their doctor if they are taking any of the following medicines:
• medicines used to treat depression(e.g. fluvoxamine),
• antibioticsused to treat bacterial infections (e.g. enoxacin). due to the prolonged elimination time of Ropivacaine Kabi from the patient's body when using these medicines. The patient should avoid long-term use of Ropivacaine Kabi when using the above-mentioned medicines.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant or plans to have
a child, they should consult their doctor before using this medicine.
There is no data on the effect of ropivacaine on pregnancy or its passage into breast milk.
Before using any medicine, the patient should consult their doctor or pharmacist if they are
pregnant or breastfeeding.

Driving and using machines

Ropivacaine Kabi may cause drowsiness and slowed reactions. After receiving Ropivacaine
Kabi, the patient should not drive vehicles or operate any tools and machines until the next
day.

Ropivacaine Kabi contains sodium

Ropivacaine Kabi, 2 mg/ml, solution for injection:
This medicine contains 3.4 mg of sodium (the main component of table salt) in 1 ml of solution. This corresponds to
0.17% of the maximum recommended daily intake of sodium in the diet for adults.
Ropivacaine Kabi, 7.5 mg/ml, solution for injection:
This medicine contains 2.99 mg of sodium (the main component of table salt) in 1 ml of solution. This corresponds to
0.15% of the maximum recommended daily intake of sodium in the diet for adults.
Ropivacaine Kabi, 10 mg/ml, solution for injection:
This medicine contains 2.8 mg of sodium (the main component of table salt) in 1 ml of solution. This corresponds to
0.14% of the maximum recommended daily intake of sodium in the diet for adults.

3. How to use Ropivacaine Kabi

Ropivacaine Kabi will be administered to the patient by a doctor. The dose of the medicine that will be administered to the patient will depend on the type of pain relief required, the patient's body weight, age and physical condition.
Ropivacaine Kabi will be administered by injection. The site of administration of Ropivacaine Kabi will depend on which part of the body needs to be numbed.
Ropivacaine Kabi may be administered in one of the following ways:

• the part of the body that is to be numbed,
• near the part of the body that is to be numbed,
• in a location away from the part of the body that is to be numbed. This is the case with epidural injection (in the area around the spinal cord). Administering Ropivacaine Kabi in one of the above ways prevents nerves from transmitting pain information to the brain. The patient will stop feeling pain, heat or cold in the area where it is applied, but may still have other sensations, such as pressure or touch.

The doctor will know how to properly administer this medicine to the patient.

Dosage

The amount of medicine administered to the patient depends on the purpose of use
and the patient's health, age and body weight.

Duration of treatment

The administration of ropivacaine usually lasts from 2 to 10 hoursin the case of numbingbefore certain
surgical procedures and may last up to 72 hoursfor pain reliefduring or after
surgical procedures.

Using a higher dose of Ropivacaine Kabi than recommended

Severe side effects resulting from the administration of too high a dose of Ropivacaine Kabi,
require specialized treatment, and the attending physician is trained in the management of such situations. The first symptoms of overdose of Ropivacaine Kabi may
include:

• hearing and vision problems (visual disturbances),
• numbness of the lips, tongue and around the mouth,
• dizziness or a feeling of "emptiness in the head",
• tingling,
• speech disorders characterized by poor articulation (dysarthria),
• muscle stiffness, muscle tremors, seizures (convulsions),
• low blood pressure,
• slow or irregular heartbeat. These symptoms may precede cardiac arrest, respiratory arrest or severe seizures. If the patient experiences any of the above symptoms or thinks they have received a higher dose of Ropivacaine Kabi than recommended, they should immediately inform their doctor or other healthcare professional. Severe side effects related to the administration of too high a dose of Ropivacaine Kabi include speech disorders, muscle tremors, tremors, shivering, seizures (seizure attacks) and loss of consciousness. If the patient experiences any of the above symptoms, they should immediately inform their doctor or other healthcare professional.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Important side effects to look out for:

Sudden life-threatening allergic reactions(such as anaphylaxis, including anaphylactic shock) are
rare and occur in 1 to 10 out of 10,000 patients. Possible symptoms include:

• sudden rash,
• itchy or lumpy rash (hives),
• swelling of the face, lips, tongue or other parts of the body,
• shortness of breath, wheezing or difficulty breathing; feeling of loss of consciousness.

If the patient thinks that Ropivacaine Kabi is causing an allergic reaction, they should immediately inform their doctor or other healthcare professionals.

Other possible side effects:

Very common(may affect more than 1 in 10 people):

• low blood pressure (hypotension), which may cause dizziness or a feeling of emptiness in the head,
• nausea (nausea). Common(may affect up to 1 in 10 people):
• feeling of tingling and numbness (paresthesia),
• dizziness,
• headache,
• slow or fast heartbeat (bradycardia, tachycardia),
• high blood pressure (hypertension),
• vomiting,
• difficulty urinating (urinary retention),
• high temperature (fever) or shivering (chills),
• muscle stiffness,
• back pain. Uncommon(may affect up to 1 in 100 people):
• restlessness,
• loss of sensation or skin sensitivity,
• fainting,
• breathing difficulties,
• drop in body temperature (hypothermia),
• some symptoms may occur as a result of unintentional intravascular administration or when the patient receives a higher dose of Ropivacaine Kabi than recommended (see also section 3 "Using a higher dose of Ropivacaine Kabi than recommended" above). These include: seizures, dizziness or a feeling of emptiness in the head, numbness of the lips and around the mouth, numbness of the tongue, hearing and vision problems, speech disorders, muscle stiffness and tremors. Rare(may affect up to 1 in 1000 people):
• heart attack (cardiac arrest),
• irregular heartbeat (arrhythmia). Frequency not known(frequency cannot be estimated from the available data):
• Horner's syndrome.

Other possible side effects:

• numbness, caused by nerve irritation caused by needle puncture or injection, usually not lasting long,
• involuntary muscle movements (dyskinesia).

Possible side effects observed with other local anesthetics, which may also be caused by Ropivacaine Kabi

include:

• nerve damage. This occurs rarely (in 1 to 10 out of 10,000 patients), may cause permanent problems,

Children

In children, side effects are the same as in adults, except for low blood pressure, which occurs less frequently in children (in 1 to 10 out of 100 children) and vomiting, which occurs more frequently in children (more than 1 in 10 children).

Reporting side effects

If side effects occur, including any not listed in this leaflet, the patient should tell their doctor or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: + 48 22 49 21 301
fax: + 48 22 49 21 309
website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, it is possible to gather more information on the safety of the medicine.

5. How to store Ropivacaine Kabi

This medicine does not require special storage conditions.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date (EXP) stated on the blister, ampoule
or carton. The expiry date refers to the last day of the month stated.
Do not use this medicine if you notice any contamination in the solution for injection.
If the medicine is not used immediately after opening, the doctor or hospital is responsible for storing and ensuring the quality of Ropivacaine Kabi, as well as for the proper disposal of unused medicine.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Ropivacaine Kabi contains

• The active substance of the medicine is ropivacaine hydrochloride: 2 mg/ml, 7.5 mg/ml, 10 mg/ml. Each 10 ml polypropylene ampoule contains 20 mg, 75 mg, 100 mg of ropivacaine hydrochloride.
• Each 20 ml polypropylene ampoule contains 40 mg, 150 mg, 200 mg of ropivacaine hydrochloride.
• The other ingredients are: sodium chloride, hydrochloric acid (to adjust pH), sodium hydroxide (to adjust pH), water for injections.

What Ropivacaine Kabi looks like and what the pack contains

Ropivacaine Kabi is a clear, colorless solution for injection.
Ropivacaine Kabi, 2 mg/ml, 7.5 mg/ml, 10 mg/ml, solution for injection is available in
transparent polypropylene ampoules with a capacity of 10 ml and 20 ml.
Pack sizes:
1, 5, 10 ampoules in a PC/PE blister pack, all in a carton.
Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder

Fresenius Kabi Polska Sp. z o.o.
Al. Jerozolimskie 134
02-305 Warsaw

Manufacturer

HP Halden Pharma AS
Svinesundsveien 80
1788 Halden
Norway
To obtain more detailed information about this medicine, please contact the marketing authorization holder:
Fresenius Kabi Polska Sp. z o.o.
Al. Jerozolimskie 134
02-305 Warsaw
tel.: +48 22 345 67 89

This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Ropivacaine Kabi, 2 mg/ml, solution for injection

Ropivacaine Kabi, 7.5 mg/ml, solution for injection

Ropivacaine Kabi, 10 mg/ml, solution for injection

Date of last revision of the leaflet:08.11.2024
---------------------------------------------------------------------------------------------------------------------------
Information intended for healthcare professionals only:
Preparation for use
Ropivacaine Kabi should only be administered by or under the supervision of physicians
experienced in the administration of regional anesthesia (see section 3).
Shelf life after opening
Use immediately.
Ropivacaine Kabi is for single use only.
Any unused solution should be discarded.
The medicine should be inspected visually before use. The solution should only be used if it is
clear, free of particles and its packaging is undamaged.
Packaging should not be subjected to re-sterilization in an autoclave.
Incompatibilities
No compatibility studies have been performed, so this medicine should not be mixed with other medicines.
In alkaline solutions, precipitation may occur, as ropivacaine has poor solubility at pH > 6.0.
Disposal of unused medicine
Any unused medicine or waste material should be disposed of in accordance with local regulations.